Taysha Gene Therapies (TSHA) Institutional Ownership
13F filers reported holding 39.2% of Taysha Gene Therapies (TSHA) shares as of Sep 30, 2026, across 135 filers.
- Held by 13F filers
- 39.2%
- Sep 30, 2026
- 13F filers
- 135
- quarter ended Sep 30, 2026
- 13F value
- $622.1M
- 127.7M shares
- Quarter's fund flow
- Mild accumulation
- 19 new · 16 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumar | President and Head of R&D | Disposed · Open-market sale | 200,000 | $6.24 | ↗ |
| Jun 1, 2026 | Long Alison S | director | Acquired · Grant / award | 21,335 | — | ↗ |
| Jun 1, 2026 | Long Alison S | director | Acquired · Grant / award | 42,671Stock Option (right to buy) | — | ↗ |
| Jun 1, 2026 | Sepp-Lorenzino Laura | director | Acquired · Grant / award | 21,335 | — | ↗ |
| Jun 1, 2026 | Sepp-Lorenzino Laura | director | Acquired · Grant / award | 42,671Stock Option (right to buy) | — | ↗ |
| Jun 1, 2026 | Stalfort Sean | director | Acquired · Grant / award | 21,335 | — | ↗ |
| Jun 1, 2026 | Stalfort Sean | director | Acquired · Grant / award | 42,671Stock Option (right to buy) | — | ↗ |
| Jun 1, 2026 | DONENBERG PHILIP B | director | Acquired · Grant / award | 21,335 | — | ↗ |
| Jun 1, 2026 | DONENBERG PHILIP B | director | Acquired · Grant / award | 42,671Stock Option (right to buy) | — | ↗ |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | Acquired · Option exercise | 19,021 | $1.71 | ↗ |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | Disposed · Open-market sale | 200,000 | $4.46 | ↗ |
| Apr 10, 2026 | Nagendran Sukumar | President and Head of R&D | Disposed · Option exercise | 19,021Employee Stock Option (right to buy) | — | ↗ |
| Feb 4, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 1,655 | $4.52 | ↗ |
| Jan 26, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 23,849 | $4.61 | ↗ |
| Jan 26, 2026 | Nagendran Sukumar | President and Head of R&D | Disposed · Open-market sale | 26,918 | $4.61 | ↗ |
| Jan 26, 2026 | Nolan Sean P. | Chief Executive Officer | Disposed · Open-market sale | 41,312 | $4.61 | ↗ |
| Jan 23, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Disposed · Open-market sale | 78,968 | $4.75 | ↗ |
| Jan 23, 2026 | Nagendran Sukumar | President and Head of R&D | Disposed · Open-market sale | 89,132 | $4.75 | ↗ |
| Jan 23, 2026 | Nolan Sean P. | Chief Executive Officer | Disposed · Open-market sale | 136,789 | $4.75 | ↗ |
| Jan 12, 2026 | Alam Kamran | CHIEF FINANCIAL OFFICER | Acquired · Grant / award | 359,000 | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Taysha Gene Therapies do institutions hold?
13F filers reported holding 39.2% of Taysha Gene Therapies' shares as of Sep 30, 2026, across 135 filers.
How many 13F filers hold Taysha Gene Therapies?
Taysha Gene Therapies was held by 135 13F filers as of Sep 30, 2026.
Not investment advice.

